OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

Registry ID
LUM001-501
Source registry
HEALTH_CANADA
Status
Closed
Study type
INTERVENTIONAL
Sponsor
LUMENA PHARMACEUTICALS INC
Completion date
2019-03-26
Last update
2014-02-06

Conditions

View on source registry